A Review of the Role of Type 2 Diabetes Mellitus and Sodium-Glucose Cotransporter-1 Inhibitors in Heart Failure With Preserved Ejection Fraction

Authors

Gladys I. Palaguachi, From the Department of Medicine, Mount Sinai South Nassau, Oceanside, NY.
William Frishman, Department of Medicine, New York Medical College/Westchester Medical Center, Valhalla, NY.Follow

Author Type(s)

Faculty

DOI

10.1097/CRD.0000000000000399

Journal Title

Cardiology in Review

First Page

274

Last Page

278

Document Type

Article

Publication Date

9-1-2022

Department

Medicine

Abstract

Previous research has demonstrated that patients with type 2 diabetes (T2DM) are at an increased risk for cardiovascular events, including heart failure (HF). Moreover, there is a higher risk of mortality in individuals who have both T2DM and HF with preserved ejection fraction (HFpEF). Although there are antidiabetic agents that have shown both cardiovascular safety and improved cardiovascular outcomes, only certain agents have been associated with HF benefits, such as sodium-glucose cotransporter-2 (SGLT2) inhibitors. This study aims to review the pathophysiology of HFpEF in the setting of T2DM and, more specifically, the role of SGLT2 inhibitors in HFpEF outcomes.

Recommended Citation

Palaguachi, G. I., & Frishman, W. (2022). A Review of the Role of Type 2 Diabetes Mellitus and Sodium-Glucose Cotransporter-1 Inhibitors in Heart Failure With Preserved Ejection Fraction. Cardiology in Review, 30 (5), 274-278. https://doi.org/10.1097/CRD.0000000000000399